Search

Your search keyword '"Snijders, Tjeerd J.F."' showing total 22 results
Start Over "Snijders, Tjeerd J.F."
22 results on '"Snijders, Tjeerd J.F."'

1. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry

Author

Brink, Mirian, primary, Huisman, Francien, additional, Meeuwes, Frederik Okko, additional, van der Poel, Marjolein W.M, additional, Kersten, Marie José, additional, Wondergem, Marielle J, additional, Bohmer, Lara H., additional, Woei-A-Jin, F.J. Sherida H., additional, Visser, Otto J., additional, Oostvogels, Rimke, additional, Jansen, Patty M, additional, Diepstra, Arjan, additional, Snijders, Tjeerd J.F., additional, Huls, Gerwin A, additional, Vermaat, Joost S.P., additional, Plattel, Wouter J., additional, and Nijland, Marcel, additional

Published
2024
Full Text
View/download PDF

2. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis

Author

Meeuwes, Frederik O., Brink, Mirian, van der Poel, Marjolein W.M., Kersten, Marie José, Wondergem, Mariëlle, Mutsaers, Pim G.N.J., Böhmer, Lara, Woei-A-Jin, Sherida, Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Diepstra, Arjan, Snijders, Tjeerd J.F., Plattel, Wouter J., Huls, Gerwin A., Vermaat, Joost S.P., and Nijland, Marcel

Published
2022
Full Text
View/download PDF

3. The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide.

Author

von dem Borne, Peter A., Kemps-Mols, Berit M., de Wreede, Liesbeth C., van Beek, Adriaan A., Snijders, Tjeerd J.F., van Lammeren, Daniëlle, Tijmensen, Janneke, Sijs-Szabó, Aniko, Oudshoorn, Mirjam A., Halkes, Constantijn J.M, van Balen, Peter, Marijt, W.A. Erik, Tjon, Jennifer M.L., Vermaat, Joost S.P, and Veelken, Hendrik

Abstract

Cytokine release syndrome (CRS) occurs frequently after haplo-identical allogeneic stem cell transplantation (alloSCT) with post-transplant cyclophosphamide (PTCy), increasing nonrelapse mortality (NRM) and decreasing survival. Data on CRS in HLA-matched alloSCT are limited and effects of specific HLA-mismatches on CRS development unknown. We hypothesized that in HLA-matched alloSCT increasing degrees of HLA-mismatching influence CRS incidence, NRM and survival. Retrospective analysis of 126 HLA-matched PTCy-alloSCT patients showed that higher degrees of HLA-mismatching significantly increased CRS incidence (26%, 75% and 90% CRS with 12/12, 10/10 and 9/10 matched donors, respectively). Maximum temperature during CRS increased with higher HLA-mismatch. Specific associations between HLA-mismatches and CRS could be determined. Grade 2 CRS and CRS-induced grade 3 fever were associated with significantly increased NRM (p < 0.001 and p = 0.003, respectively) and inferior survival (p < 0.001 and p = 0.005, respectively). NRM was mainly caused by disease conditions that may be considered CRS-induced inflammatory responses (encephalopathy, cryptogenic organizing pneumonia and multi-organ failure). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands

Author

Meeuwes, Frederik O., primary, Brink, Mirian, additional, Plattel, Wouter, additional, Van der Poel, Marjolein W.M., additional, Kersten, Marie José, additional, Wondergem, Mariëlle, additional, Böhmer, Lara, additional, Woei-A-Jin, F.J. Sherida H., additional, Visser, Otto, additional, Oostvogels, Rimke, additional, Jansen, Patty M., additional, Neelis, Karen J., additional, Crijns, Anne P.G., additional, Daniëls, Laurien A., additional, Snijders, Tjeerd J.F., additional, Vermaat, Joost S.P., additional, Huls, Gerwin A., additional, and Nijland, Marcel, additional

Published
2023
Full Text
View/download PDF

5. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion

Author

Koster, Eva A.S., von dem Borne, Peter A., van Balen, Peter, van Egmond, Esther H.M., Marijt, Erik W.A., Veld, Sabrina A.J., Jedema, Inge, Snijders, Tjeerd J.F., van Lammeren, Daniëlle, Veelken, Hendrik, Falkenburg, J.H. Frederik, de Wreede, Liesbeth C., and Halkes, Constantijn J.M.

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 3 from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., primary, Spanholtz, Jan, primary, Hangalapura, Basav N., primary, Tordoir, Marleen, primary, Maas, Frans, primary, Leenders, Marij, primary, Bohme, Fenna, primary, Kok, Nina, primary, Trilsbeek, Carel, primary, Paardekooper, Jos, primary, van der Waart, Anniek B., primary, Westerweel, Peter E., primary, Snijders, Tjeerd J.F., primary, Cornelissen, Jan, primary, Bos, Gerard, primary, Pruijt, Hans F.M., primary, de Graaf, Aniek O., primary, van der Reijden, Bert A., primary, Jansen, Joop H., primary, van der Meer, Arnold, primary, Huls, Gerwin, primary, Cany, Jeannette, primary, Preijers, Frank, primary, Blijlevens, Nicole M.A., primary, and Schaap, Nicolaas M., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Information from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., primary, Spanholtz, Jan, primary, Hangalapura, Basav N., primary, Tordoir, Marleen, primary, Maas, Frans, primary, Leenders, Marij, primary, Bohme, Fenna, primary, Kok, Nina, primary, Trilsbeek, Carel, primary, Paardekooper, Jos, primary, van der Waart, Anniek B., primary, Westerweel, Peter E., primary, Snijders, Tjeerd J.F., primary, Cornelissen, Jan, primary, Bos, Gerard, primary, Pruijt, Hans F.M., primary, de Graaf, Aniek O., primary, van der Reijden, Bert A., primary, Jansen, Joop H., primary, van der Meer, Arnold, primary, Huls, Gerwin, primary, Cany, Jeannette, primary, Preijers, Frank, primary, Blijlevens, Nicole M.A., primary, and Schaap, Nicolaas M., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 1 from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., primary, Spanholtz, Jan, primary, Hangalapura, Basav N., primary, Tordoir, Marleen, primary, Maas, Frans, primary, Leenders, Marij, primary, Bohme, Fenna, primary, Kok, Nina, primary, Trilsbeek, Carel, primary, Paardekooper, Jos, primary, van der Waart, Anniek B., primary, Westerweel, Peter E., primary, Snijders, Tjeerd J.F., primary, Cornelissen, Jan, primary, Bos, Gerard, primary, Pruijt, Hans F.M., primary, de Graaf, Aniek O., primary, van der Reijden, Bert A., primary, Jansen, Joop H., primary, van der Meer, Arnold, primary, Huls, Gerwin, primary, Cany, Jeannette, primary, Preijers, Frank, primary, Blijlevens, Nicole M.A., primary, and Schaap, Nicolaas M., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 2 from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., primary, Spanholtz, Jan, primary, Hangalapura, Basav N., primary, Tordoir, Marleen, primary, Maas, Frans, primary, Leenders, Marij, primary, Bohme, Fenna, primary, Kok, Nina, primary, Trilsbeek, Carel, primary, Paardekooper, Jos, primary, van der Waart, Anniek B., primary, Westerweel, Peter E., primary, Snijders, Tjeerd J.F., primary, Cornelissen, Jan, primary, Bos, Gerard, primary, Pruijt, Hans F.M., primary, de Graaf, Aniek O., primary, van der Reijden, Bert A., primary, Jansen, Joop H., primary, van der Meer, Arnold, primary, Huls, Gerwin, primary, Cany, Jeannette, primary, Preijers, Frank, primary, Blijlevens, Nicole M.A., primary, and Schaap, Nicolaas M., primary

Published
2023
Full Text
View/download PDF

10. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion

Author

Koster, Eva A.S., primary, von dem Borne, Peter A., additional, van Balen, Peter, additional, van Egmond, Esther H.M., additional, Marijt, Erik W.A., additional, Veld, Sabrina A.J., additional, Jedema, Inge, additional, Snijders, Tjeerd J.F., additional, van Lammeren, Daniëlle, additional, Veelken, Hendrik, additional, Falkenburg, J.H. Frederik, additional, de Wreede, Liesbeth C., additional, and Halkes, Constantijn J.M., additional

Published
2022
Full Text
View/download PDF

11. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Author

Kersten, Marie José, primary, Dreyling, Martin, additional, Linton, Kim M., additional, Chitu, Dana, additional, Tonino, Sanne, additional, Kap, Marcel, additional, Liu, Roberto D, additional, Chamuleau, Martine E.D., additional, Visser, Hein P.J., additional, De Jongh, Eva, additional, Marijt, Erik WAF, additional, Leijs, Maria B.L., additional, Bilgin, Yavuz M., additional, Dürig, Jan, additional, McKay, Pamela, additional, Snijders, Tjeerd J.F., additional, Pettitt, Andrew, additional, Minnema, Monique C., additional, Prange-Krex, Gabriele, additional, Cuijpers, Maria, additional, Böhmer, Lara H., additional, Tick, Lidwine W., additional, Florschütz, Axel, additional, Silbermann, Matthijs, additional, Fijnheer, Rob, additional, Beeker, Aart, additional, Tolboom, Nelleke, additional, Mitea, Cristina, additional, Arens, Anne IJ, additional, Zwezerijnen, Gerben JC, additional, Klapper, Wolfram, additional, Coupland, Sarah E., additional, de Jong, Daphne, additional, Doorduijn, Jeanette K., additional, and Zijlstra, Josée M., additional

Published
2022
Full Text
View/download PDF

12. Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia

Author

Von Dem Borne, Peter A., primary, Snijders, Tjeerd J.F., additional, van Lammeren, Danielle, additional, Tijmensen, Janneke, additional, Planken, Erwin V., additional, Levenga, Henriette, additional, van den Berg, Yascha, additional, Marijt, Erik WAF, additional, van Balen, Peter, additional, Tjon, Jennifer M., additional, Vermaat, Joost S.P., additional, Nering Bögel, Theo L., additional, Oudshoorn, Mirjam A., additional, Halkes, Constantijn J.M., additional, and Veelken, Hendrik, additional

Published
2022
Full Text
View/download PDF

13. Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

Author

Wang, Steven, primary, Drees, Esther E.E., additional, Gómez-Martín, Cristina, additional, De Jonge, A., additional, van Eijndhoven, Monique, additional, Groenewegen, Nils, additional, Veldt-Verkuijlen, Sandra, additional, Nijland, Marcel, additional, Van Der Poel, Marjolein W.M., additional, Sandberg, Yorick, additional, van Rijn, Rozemarijn, additional, Mutsaers, Pim, additional, Vergote, Vibeke K.J., additional, Kersten, Marie José, additional, Bilgin, Yavuz M., additional, Stevens, Wendy B.C., additional, Durian, Marc, additional, Snijders, Tjeerd J.F., additional, de Jong, Daphne, additional, Zijlstra, Josée M., additional, Chamuleau, Martine E.D., additional, and Pegtel, Dirk Michiel, additional

Published
2022
Full Text
View/download PDF

14. Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Author

Von Dem Borne, Peter A., primary, Kemps-Mols, Berit M., additional, de Wreede, Liesbeth C., additional, van Beek, Adriaan A., additional, Snijders, Tjeerd J.F., additional, van Lammeren, Danielle, additional, Tijmensen, Janneke, additional, Sijs-Szabo, Aniko, additional, Nering Bögel, Theo L., additional, Oudshoorn, Mirjam A., additional, Halkes, Constantijn J.M., additional, van Balen, Peter, additional, Marijt, Erik W.A.F., additional, Tjon, Jennifer M.L., additional, Vermaat, Joost S.P., additional, and Veelken, Hendrik, additional

Published
2022
Full Text
View/download PDF

16. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phaselenalidomide:II HOVON trial results of a multicenter

Author

Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S.P., Marijt, Eric A.F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J.F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I.J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, and Kersten, Marie José

Abstract

atients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients without MYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in newly diagnosed MYC+ LBCL patients identified through a nationwide MYCFISH screening program. The primary endpoint was complete metabolic response (CMR) on centrally reviewed 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computer tomography (CT)-scan at end-of-treatment. Secondary endpoints were overall survival (OS), disease-free survival (DFS) and event-free survival (EFS). Eighty-two patients with stage II-IV MYC+ LBCL were treated with six cycles of R2CHOP. At end of treatment, 67% (95% Confidence interval [CI]: 58-75) of the patients reached CMR. With a median follow-up of 25.4 months, 2-year estimates for OS, DFS, EFS were 73% (95% CI: 62-82), 75% (95% CI: 63-84) and 63% change to: (95% CI: 52-73) respectively. In this prospective trial for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yields comparable CMR and survival rates as in studies applying more intensive chemotherapy regimens. Hence, these findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized clinical trials. This trial was registered at www.clinicaltrialsregister.eu (#2014-002654-39).

Published
2020

17. Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

Author

Doorduijn, Jeanette K., primary, Zijlstra, Josee M., additional, Lugtenburg, Pieternella J., additional, Kersten, Marie Josee, additional, Böhmer, Lara H., additional, Minnema, Monique C., additional, MacKenzie, Marius A., additional, van Marwijk Kooij, Rien, additional, Jongh, Eva, additional, Snijders, Tjeerd J.F., additional, Weerdt, Okke, additional, Gelder, Michel, additional, Hoogendoorn, Mels, additional, Leys, Rineke B.L., additional, Kibbelaar, Robby E., additional, Jong, Daphne, additional, Chitu, Dana A., additional, Van’t Veer, Mars B., additional, and Kluin‐Nelemans, Hanneke C., additional

Published
2020
Full Text
View/download PDF

18. Treatment strategies and outcome relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry

Author

Brink, Mirian, Huisman, Francien, Meeuwes, Frederik O., van der Poel, Marjolein W.M., Kersten, Marie José, Wondergem, Mariëlle, Böhmer, Lara, Woei-A-Jin, F.J. Sherida H., Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Diepstra, Arjan, Snijders, Tjeerd J.F., Huls, Gerwin, Vermaat, Joost S.P., Plattel, Wouter J., and Nijland, Marcel

Abstract

•In relapsed PTCL response to salvage chemotherapy is poor with only a minority of patients proceeding to stem cell transplantation•Risk of second relapse is half for patients treated with brentuximab vedotin compared to chemotherapy, independent of histological subtype

Published
2024
Full Text
View/download PDF

19. Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., additional, Spanholtz, Jan, additional, Hangalapura, Basav N., additional, Tordoir, Marleen, additional, Maas, Frans, additional, Leenders, Marij, additional, Bohme, Fenna, additional, Kok, Nina, additional, Trilsbeek, Carel, additional, Paardekooper, Jos, additional, van der Waart, Anniek B., additional, Westerweel, Peter E., additional, Snijders, Tjeerd J.F., additional, Cornelissen, Jan, additional, Bos, Gerard, additional, Pruijt, Hans F.M., additional, de Graaf, Aniek O., additional, van der Reijden, Bert A., additional, Jansen, Joop H., additional, van der Meer, Arnold, additional, Huls, Gerwin, additional, Cany, Jeannette, additional, Preijers, Frank, additional, Blijlevens, Nicole M.A., additional, and Schaap, Nicolaas M., additional

Published
2017
Full Text
View/download PDF

20. Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia

Author

Tjon, Jennifer M-L., primary, de Groot, Marco R., additional, Sypkens Smit, Saskia M.A., additional, de Wreede, Liesbeth C., additional, Snijders, Tjeerd J.F., additional, Koene, Harry R., additional, Meijer, Ellen, additional, Raaijmakers, Marc H.G., additional, Schaap, Michel, additional, Raymakers, Reinier, additional, Zeerleder, Sacha S., additional, and Halkes, Constantijn J.M., additional

Published
2016
Full Text
View/download PDF

21. A Phase I Study of Allogeneic Natural Killer Cell Therapy Generated from Cord Blood Hematopoietic Stem and Progenitor Cells in Elderly Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., additional, Spanholtz, Jan, additional, Hangalapura, Basav, additional, Tordoir, Marleen, additional, Maas, Frans, additional, Leenders, Marij, additional, Bohme, Fenna, additional, Kok, Nina, additional, Trilsbeek, Carel, additional, Paardekooper, Jos, additional, Van der Waart, Anniek B., additional, Westerweel, Peter, additional, Snijders, Tjeerd J.F., additional, Bos, Gerard M.J., additional, Cornelissen, Jan J., additional, Pruijt, Hans, additional, Huls, Gerwin, additional, de Graaf, Aniek, additional, van der Reijden, Bert A., additional, Blijlevens, Nicole M.A., additional, Jansen, Joop H., additional, van der Meer, Arnold, additional, Cany, Jeannette, additional, Preijers, Frank, additional, and Schaap, Nicolaas P.M., additional

Published
2015
Full Text
View/download PDF

22. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma:a population-based analysis

Abstract

Background: Patients with angioimmunoblastic T-cell lymphoma (AITL) are treated with cyclophosphamide, doxorubicin, vincristine and prednisone with or without etoposide (CHO(E)P). In the majority of cases, Epstein–Barr virus (EBV)-positive B-cells are present in the tumour. There is paucity of research examining the effect of rituximab when added to CHO(E)P. In this nationwide, population-based study, we analysed the impact of rituximab on overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) of patients with AITL. Methods: Patients with AITL diagnosed between 2014 and 2020 treated with ≥one cycle of CHO(E)P with or without rituximab were identified in the Netherlands Cancer Registry. Survival follow-up was up to 1st February 2022. Baseline characteristics, best response during first-line treatment and survival were collected. PFS was defined as the time from diagnosis to relapse or to all-cause-death. OS was defined as the time from diagnosis to all-cause-death. Multivariable analysis for the risk of mortality was performed using Cox regression. Findings: Out of 335 patients, 146 patients (44%) received R–CHO(E)P. Rituximab was more frequently used in patients with a B-cell infiltrate (71% versus 89%, p < 0·01). The proportion of patients who received autologous stem cell transplantation (ASCT) was similar between CHO(E)P and R–CHO(E)P (27% versus 30%, respectively). The ORR and 2-year PFS for patients who received CHO(E)P and R–CHO(E)P were 71% and 78% (p = 0·01), and 40% and 45% (p = 0·12), respectively. The 5-year OS was 47% and 40% (p = 0·99), respectively. In multivariable analysis, IPI-score 3–5, no B-cell infiltrate and no ASCT were independent prognostic factors for risk of mortality, whereas the use of rituximab was not. Interpretation: Although the addition of rituximab to CHO(E)P improved ORR for patients with AITL, the PFS and OS did not improve.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results